학술논문
Concomitant Mitral Regurgitation in Severe Aortic Stenosis ― A Report From the CURRENT AS Registry ―
Document Type
Journal Article
Author
Akihiro Komasa; Atsushi Iwakura; Chisato Izumi; Chiyo Maeda; Eiji Shinoda; Eri Minamino-Muta; Fumio Yamazaki; Genichi Sakaguchi; Hirokazu Mitsuoka; Hiroki Sakamoto; Hiroshi Eizawa; Hiroshi Mabuchi; Hiroyuki Nakajima; Ichiro Kouchi; Junichiro Nishizawa; Katsuhisa Ishii; Kazuo Yamanaka; Kazushige Kadota; Kazuya Nagao; Keiichi Fujiwara; Keiichiro Yamane; Kenji Ando; Kenji Minatoya; Koichiro Murata; Koji Ueyama; Kotaro Shiraga; Kozo Hotta; Makoto Miyake; Mamoru Toyofuku; Manabu Shirotani; Masaharu Akao; Masanobu Ohya; Masashi Kato; Michiya Hanyu; Mitsuo Matsuda; Mitsuru Ishii; Mitsuru Kitano; Moriaki Inoko; Nobuya Higashitani; Norio Kanamori; Ryosuke Murai; Sachiko Sugioka; Senri Miwa; Shigeru Ikeguchi; Shinji Miki; Shintaro Matsuda; Shogo Nakayama; Shouji Kitaguchi; Shunichi Miyazaki; Tadaaki Koyama; Takao Kato; Takashi Tamura; Takenobu Shimada; Takeshi Aoyama; Takeshi Kimura; Takeshi Kitai; Takeshi Maruo; Takeshi Morimoto; Tatsuhiko Komiya; Tatsuya Ogawa; Tomohiko Taniguchi; Tomoya Onodera; Tomoyuki Ikeda; Toshihiko Saga; Toshikazu Jinnai; Tsukasa Inada; Yasushi Fuku; Yasutaka Inuzuka; Yasuyo Takeuchi; Yoshihiro Himura; Yoshihiro Kato; Yoshihisa Nakagawa; Yuichi Kawase; Yukihito Sato; Yuko Morikami; Yutaka Furukawa; Yutaka Hirano; on behalf of the CURRENT AS Registry Investigators
Source
Circulation Journal. 2022, 86(3):427
Subject
Language
English
ISSN
1346-9843
1347-4820
1347-4820
Abstract
Methods and Results:We analyzed 3,815 patients from a retrospective multicenter registry of severe AS in Japan (CURRENT AS registry). We compared the clinical outcomes between patients with moderate/severe MR and with none/mild MR according to the initial treatment strategy (initial aortic valve replacement [AVR] or conservative strategy). The primary outcome measure was a composite of aortic valve-related death or heart failure hospitalization. At baseline, moderate/severe MR was present in 227/1,197 (19%) patients with initial AVR strategy and in 536/2,618 (20%) patients with a conservative strategy. The crude cumulative 5-year incidence of the primary outcome measure was significantly higher in patients with moderate/severe MR than in those with none/mild MR, regardless of the initial treatment strategy (25.2% vs. 14.4%, P<0.001 in the initial AVR strategy, and 63.3% vs. 40.7%, P<0.001 in the conservative strategy). After adjusting confounders, moderate/severe MR was not independently associated with higher risk for the primary outcome measure in the initial AVR strategy (hazard ratio [HR] 1.11, 95% confidence interval [CI] 0.67–1.83, P=0.69), and in the conservative strategy (HR 1.13, 95% CI 0.93–1.37, P=0.22).